Mirum Pharmaceuticals (MIRM) Projected to Post Earnings on Wednesday

Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to be releasing its earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $96.64 million for the quarter.

Mirum Pharmaceuticals Trading Up 5.3 %

Shares of Mirum Pharmaceuticals stock opened at $52.70 on Wednesday. The stock has a fifty day simple moving average of $45.44 and a 200 day simple moving average of $42.74. Mirum Pharmaceuticals has a 12-month low of $23.14 and a 12-month high of $53.49. The company has a market capitalization of $2.53 billion, a P/E ratio of -26.09 and a beta of 0.96. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 750 shares of the business’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $32,115.00. Following the transaction, the senior vice president now owns 2,926 shares of the company’s stock, valued at approximately $125,291.32. The trade was a 20.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Christopher Peetz sold 7,489 shares of the company’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $320,678.98. Following the transaction, the chief executive officer now directly owns 119,359 shares in the company, valued at $5,110,952.38. This represents a 5.90 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 40,915 shares of company stock valued at $1,897,920. Insiders own 22.87% of the company’s stock.

Wall Street Analysts Forecast Growth

MIRM has been the subject of several recent research reports. Robert W. Baird upped their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Citigroup upped their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $66.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Mirum Pharmaceuticals currently has an average rating of “Buy” and an average price target of $57.10.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.